Researcher profile
Dominic Oliver
Affiliations
Organizations
Public evidence
9 connected articles
Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis2026 · medRxivDoes cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.2025 · Europe PMCPSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample.2025 · Europe PMCLongitudinal evolution of the transdiagnostic prodrome to severe mental disorders: a dynamic temporal network analysis informed by natural language processing and electronic health records.2025 · Europe PMCExploring the relationship between frequent cannabis use, belief updating under uncertainty and psychotic-like symptoms.2024 · Europe PMCCannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.2024 · Europe PMCInfluence of cannabis use on incidence of psychosis in people at clinical high risk.2023 · Europe PMCDoes cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.2023 · Europe PMCCannabidiol (CBD) as a novel treatment in the early phases of psychosis.2022 · Europe PMC
Registered research
Connected studies
Matched by exact identifiers only. Profile data: Corpus/OpenAlex.